Pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning

Patent metadata

Field	Value
Publication number	US-2016136183-A1
Application number	US-201414899162-A
Country	US
Kind code	A1
Filing date	Jun 20, 2014
Priority date	Jun 21, 2013
Publication date	May 19, 2016
Grant date	—

Abstract

The present invention relates to method and pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning. In particular, the present invention relates to a mineralocorticoid receptor antagonist for topical use in a method for preventing or reducing glucocorticoid-induced corneal or skin thinning in a subject in need thereof. The invention also relates to a topical pharmaceutical composition comprising an amount of at least one glucocorticoid and an amount of at least one mineralocorticoid receptor antagonist or inhibitor of MR expression for use in a method for treating an inflammatory skin disease or an inflammatory disease of the cornea or of the anterior segment of the eye in a subject in need thereof.

First claim

1 . A method for preventing or reducing glucocorticoid-induced corneal or skin thinning in a subject in need thereof comprising
administering to the subject a therapeutically effective amount of a mineralocorticoid receptor antagonist, wherein said therapeutically effective amount is sufficient to prevent or reduce the glucocorticoid-induced corneal or skin thinning in the subject.

2 . The method according to claim 1 wherein the subject suffers of a skin disease selected from the group consisting of eczema, psoriasis, allergic dermatitis, neurodermatitis, pruritis, exfoliative dermatitis, pemphigus and hypersensitivity reactions.

3 . The method according to claim 1 wherein the subject suffers of an ocular disease selected from the group consisting of uveitis, blepharitis, conjunctivitis, scleritis, and postoperative inflammation.

4 . The method of claim 1 wherein the subject was treated with a glucocorticoid selected from the group consisting of 21-acetoxypregnenolone, alclometasone, algestone, amcinonide, beclomethasone, betamethasone, budesonide, chloroprednisone, clobetasol, clobetasone, clocortolone, cloprednol, corticosterone, cortisone, cortivazol, deflazacort, desonide, desoximetasone, dexamethasone, diflorasone, diflucortolone, difluprednate, enoxolone, fluazacort, flucloronide, flumethasone, flunisolide, fluocinolone acetonide, fluocinonide, fluocortin butyl, fluocortolone, fluorometholone, fluperolone acetate, fluprednidene acetate, fluprednisolone, flurandrenolide, fluticasone propionate, formocortal, halcinonide, halobetasol propionate, halometasone, halopredone acetate, hydrocortamate, hydrocortisone, loteprednol etabonate, mazipredone, medrysone, meprednisone, methylprednisolone, mometasone furoate, paramethasone, prednicarbate, prednisolone, prednisolone 25-diethylamino-acetate, prednisolone sodium phosphate, prednisone, prednival, prednylidene, rimexolone, tixocortol, triamcinolone, triamcinolone acetonide, triamcinolone benetonide, triamcinolone hexacetonide, anecortave acetate or a derivative of any of these glucocorticoids.

5 . The method of claim 1 wherein the mineralocorticoid receptor antagonist is a steroidal mineralocorticoid receptor antagonist or a non-steroidal mineralocorticoid receptor antagonist.

6 . The method of claim 5 wherein the mineralocorticoid receptor antagonist is spironolactone or eplerenone.

7 . The method of claim 1 wherein the mineralocorticoid receptor antagonist is topically administered to the subject.

8 . A method for preventing or reducing glucocorticoid-induced corneal or skin thinning in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an inhibitor of mineralocorticoid receptor expression, wherein the therapeutically effective amount is sufficient to prevent or reduce the glucocorticoid-induced corneal or skin thinning in the subject.

9 . A method for treating an inflammatory skin disease or an inflammatory disease of the cornea or of the anterior segment of the eye in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising at least one glucocorticoid and at least one mineralocorticoid receptor antagonist or inhibitor of MR expression glucocorticoid-induced corneal or skin thinning, wherein the therapeutically effective amount is sufficient to treat the inflammatory skin disease or the inflammatory disease of the cornea or of the anterior segment of the eye in the subject.

10 . The method according to claim 9 , wherein the pharmaceutical composition is formulated as a cream, an ointment, or gel.

11 . The method according to claim 9 , wherein the pharmaceutical composition is formulated as an ophthalmic drop or an ophthalmic ointment.

Assignees

• Inst Nat Sante Rech Med
• Univ Paris Descartes
• Univ Pierre Et Marie Curie Paris 6
• Assist Publ Hopitaux De Paris

Inventors

• Farman Nicolette
• Jaisser Frederic
• Behar-Cohen Francine
• Aractingi Selin
• Nguyen Van Tuan

Classifications

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61P17/00

  Drugs for dermatological disorders · CPC title

• A61K9/0048

  Eye, e.g. artificial tears · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title